Abstract
The present article descibes the use of TNF inhibitors in paediatrics, with special focus on etanercept, infliximab and adalimumab. Their molecular structure and mechanism of action are accurately described. Licensed and sperimental applications are discussed, with particular reference to rheumatic and gastroenterological field. Side effects in the short and long term are referred and the cost-effectiveness of anti-TNF drugs is taken into account. The article will show how etanercept in rheumatology and infliximab in gastroenterology have given new hope to patients with inflammatory diseases refractory to other treatments.
| Original language | Italian |
|---|---|
| Pages (from-to) | 314-321 |
| Number of pages | 8 |
| Journal | Medico e Bambino |
| Volume | 31 |
| Issue number | 5 |
| Publication status | Published - May 2012 |
Fingerprint
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Cite this
Gli inibitori del TNF alfa nella cura delle malattie infiammatorie croniche : Luci e ombre. / Gortani, Giulia; Martelossi, Stefano; Lepore, Loredana.
In: Medico e Bambino, Vol. 31, No. 5, 05.2012, p. 314-321.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Gli inibitori del TNF alfa nella cura delle malattie infiammatorie croniche
T2 - Luci e ombre
AU - Gortani, Giulia
AU - Martelossi, Stefano
AU - Lepore, Loredana
PY - 2012/5
Y1 - 2012/5
N2 - The present article descibes the use of TNF inhibitors in paediatrics, with special focus on etanercept, infliximab and adalimumab. Their molecular structure and mechanism of action are accurately described. Licensed and sperimental applications are discussed, with particular reference to rheumatic and gastroenterological field. Side effects in the short and long term are referred and the cost-effectiveness of anti-TNF drugs is taken into account. The article will show how etanercept in rheumatology and infliximab in gastroenterology have given new hope to patients with inflammatory diseases refractory to other treatments.
AB - The present article descibes the use of TNF inhibitors in paediatrics, with special focus on etanercept, infliximab and adalimumab. Their molecular structure and mechanism of action are accurately described. Licensed and sperimental applications are discussed, with particular reference to rheumatic and gastroenterological field. Side effects in the short and long term are referred and the cost-effectiveness of anti-TNF drugs is taken into account. The article will show how etanercept in rheumatology and infliximab in gastroenterology have given new hope to patients with inflammatory diseases refractory to other treatments.
KW - Anti-TNF drugs
KW - Chronic inflammatory disorders
KW - TNF inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84861677700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861677700&partnerID=8YFLogxK
M3 - Articolo
VL - 31
SP - 314
EP - 321
JO - Medico e Bambino
JF - Medico e Bambino
SN - 1591-3090
IS - 5
ER -